金币
UID176556
帖子
主题
积分25293
注册时间2014-6-6
最后登录1970-1-1
听众
性别保密
|
欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
本帖最后由 beiwei5du 于 2016-10-5 20:30 编辑
各位蒲友:
又看到FDA process validation:general principles and practices(2011)里有这么一句话:
In addition to sampling requirements, the CGMP regulations also provide norms for establishingin-process specifications as an aspect of process validation. Section 211.110(b) establishes twoprinciples to follow when establishing in-process specifications.
The first principle is that “. . .in-process specifications for such characteristics [of in-process material and the drug product]shall be consistent with drug product final specifications . . . .” Accordingly, in-process materialshould be controlled to assure that the final drug product will meet its quality requirements. (第一条原则是不是:将中间控制标准和最终成品的标准制定成一致,比如最终成品的某一单杂≤0.05%,那么在中间控制标准也制定为≤0.05%)
Thesecond principle in this regulation further requires that in-process specifications “. . . shall bederived from previous acceptable process average and process variability estimates wherepossible and determined by the application of suitable statistical procedures where appropriate.”This requirement, in part, establishes the need for manufacturers to analyze process performanceand control batch-to-batch variability.
(第二条原则是不是:不将中间控制标准和最终成品标准的制定一致,而是通过以前平均值和使用统计方式求出工序能力,比如原来平均标准为某一单杂0.15%,加上统计算为0.14%-0.16%的标准,而最终成品的标准制定为≤0.05%,前提是中间控制标准控制在0.14%-0.16%范围内,后期的最终成品的标准能控制在≤0.05%)
到底是什么意思呢??没有搞懂!。求指教!@hongwei2000 @意林枫 @Sword
|
|